Visão geral da empresa
A biotechnology firm focused on the discovery and development of oral covalent small molecule drugs, Biomea Fusion, Inc. targets the treatment of metabolic diseases such as diabetes and obesity specifically within the United States market. The company operates within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself as a clinical-stage entity dedicated to delivering innovative pharmaceutical solutions. As of the latest available data, the organization maintains a market capitalization of $133.75M and employs a workforce of 41 individuals to advance its research and development pipeline. The current market valuation indicates a mid-cap status for a clinical-stage biotechnology company, suggesting significant potential for capital appreciation while simultaneously reflecting the high risk and early-stage nature of its product development cycle, where revenue generation is currently not yet realized.
Saúde financeira
The financial statements for Biomea Fusion, Inc. report revenue over the trailing twelve months as N/A, with a net income of $-61,797,000 and an EBITDA of $-79,898,000. The substantial gap between reported revenue figures and the significant net loss highlights a cost structure heavily dominated by research and development expenses rather than commercial sales costs. The company generated a free cash flow of $-42,026,876 during the period, which indicates that current operations are consuming cash reserves to fund future growth initiatives rather than generating liquidity. The company holds cash assets totaling $55.81M against total debt obligations of $1.59M, resulting in a debt-to-equity ratio of 5.38 which suggests a highly leveraged capital structure typical for pre-revenue biotechnology firms. Although the debt load is significant relative to equity, the current ratio stands at 5.23, indicating a robust short-term liquidity position that provides ample coverage for immediate obligations. Profitability metrics are reflected by a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, all of which are consistent with a clinical-stage business model that prioritizes product development over current profitability. Return on Equity is recorded at -152.4% and Return on Assets at -73.4%, revealing that management effectiveness in generating returns is currently negative due to the heavy investment required to advance the lead product candidate icovamenib through clinical trials.
Avaliação de valorização
Valuation multiples for Biomea Fusion, Inc. show a P/E Ratio (TTM) of N/A and a Forward P/E of -1.74, implying that earnings are currently negative and future earnings projections are not sufficient to establish a traditional positive price-to-earnings multiple at this time. The price-to-book ratio is listed at 4.52, indicating that the market values the company at a significant premium over its book value, a common characteristic for asset-light biotechnology firms where intellectual property holds the primary value. Alternative valuation metrics include a Price to Sales ratio of N/A due to lack of revenue data and an EV/EBITDA of -0.99, suggesting that traditional valuation methods are less applicable until the company achieves commercialization and positive earnings. The stock price has fluctuated within a 52-week range with a high of $3.08 and a low of $0.87, placing the current trading position within a wide band that reflects high market volatility in the small-cap biotech sector. The beta value of -0.27 indicates an inverse correlation with the broader market, meaning the stock price tends to move in the opposite direction of the general market index, presenting a unique risk profile for portfolio diversification strategies.
Growth & Income
Growth metrics for the company are characterized by revenue growth year-over-year of N/A and earnings growth year-over-year of N/A, as the business has not yet reached a stage of consistent commercial sales or reported earnings. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating that the organization reinvests all available capital back into research, development, and clinical trials rather than distributing income to shareholders. The absence of a dividend yield combined with negative growth rates in traditional metrics underscores the company's strategy of funding organic growth through internal cash generation and external financing to advance its pipeline. Overall, the growth and income profile of Biomea Fusion, Inc. is defined by a focus on long-term asset creation and product pipeline advancement rather than current income generation or short-term revenue expansion.